Related references
Note: Only part of the references are listed.Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection
Samuel G. Jacobson et al.
MOLECULAR THERAPY (2006)
Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys
CM Lai et al.
MOLECULAR THERAPY (2005)
AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of α-galactosidase A and the induction of immune tolerance in Fabry mice
RJ Ziegler et al.
MOLECULAR THERAPY (2004)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier
P Gehlbach et al.
HUMAN GENE THERAPY (2003)
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
S Zolotukhin et al.
METHODS (2002)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy
YKY Lai et al.
GENE THERAPY (2002)
Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1
JWB Bainbridge et al.
GENE THERAPY (2002)
CMV-β-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1α promoter and results in therapeutic levels of human factor X in mice
LF Xu et al.
HUMAN GENE THERAPY (2001)
Share Paper
